Related Experiment Videos
Neurofibromatosis in children with soft tissue sarcoma
A L Hartley1, J M Birch, H B Marsden
1Department of Epidemiology and Social Oncology, Christie Hospital & Holt Radium Institute, Manchester, England.
Pediatric Hematology and Oncology
|January 1, 1988
Summary
Neurofibromatosis (NF) may be more common in children with soft tissue sarcoma. Clinicians should screen for NF signs in these children and their families due to potential increased malignancy risk.
Area of Science:
- Pediatric Oncology
- Genetics
- Dermatology
Background:
- Soft tissue sarcomas are rare pediatric malignancies.
- Neurofibromatosis (NF) is a genetic disorder with diverse clinical manifestations.
- The association between NF and soft tissue sarcoma in children requires further investigation.
Purpose of the Study:
- To determine the prevalence of neurofibromatosis (NF) in a cohort of children diagnosed with soft tissue sarcoma.
- To identify specific subtypes and clinical features of soft tissue sarcoma associated with NF in pediatric patients.
- To assess the potential for increased risk of secondary malignancies in children with both conditions.
Main Methods:
- Retrospective review of case records for 157 children with soft tissue sarcoma diagnosed between 1954 and 1983.
- Diagnostic features of neurofibromatosis (NF) were assessed from medical records.
- Interviews were conducted with families of 124 affected children.
Main Results:
- Four out of 157 children (2.5%) were diagnosed with neurofibromatosis (NF).
- All identified cases were boys with rhabdomyosarcomas of the bladder or prostate, diagnosed at a young age.
- Evidence suggested a potential NF diagnosis in an additional nine children.
Conclusions:
- Neurofibromatosis (NF) may be more prevalent in pediatric soft tissue sarcoma cases than previously recognized.
- Clinicians should maintain a high index of suspicion for NF in children presenting with soft tissue sarcoma and their families.
- Children with NF and soft tissue sarcoma may face an elevated risk for developing additional malignancies.